Microbot Medical (MBOT)
Commercializes the LIBERTY single-use robotic system for peripheral endovascular procedures.
Something off on this page? Send us feedback.
Commercializes LIBERTY, an FDA-cleared single-use robotic system for peripheral endovascular procedures. The company began a full U.S. market release after an earlier limited release, with initial revenue and hospital adoption; LIBERTY is the operating product after its SCS/ViRob and TipCAT programs were discontinued.
Develops and sells LIBERTY, a single-use, remotely operated robotic system for peripheral endovascular procedures. SCS/ViRob and TipCAT were earlier programs whose development was ended.
Following FDA 510(k) clearance, the company moved from a limited release to a full U.S. market release. Initial revenue and hospital adoption across several states mark the transition into commercial operations.
LIBERTY is the current operating product after Microbot Israel joined the public parent through its 2016 merger with StemCells. Founder Harel Gadot remains CEO, President, and Chairman. Its cleared peripheral-endovascular indication and hospital adoption shape the present operating structure.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Jun 3, 2026 | Loop Capital Markets | Target | $4 |
| Dec 3, 2025 | Roth Capital | Target | $5.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $67.4M · Total debt $876.0K · Total assets $73.4M · Shareholders' equity $68.9M
- Revenue
- $241.0K
- Operating income
- −$6.2M
- Net income
- −$5.6M
No dividends on record.
| Institutions86 holders · as of Mar 31, 2026 | 31.24% | 14.24M shares | |
| Insiders3 holders · as of Jan 23, 2026 | 18.76% | 8.55M shares | |
| Otherremainder | 50.00% | 22.78M shares |
45.57M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (67.16M in the company's Sep 3, 2026 report, 45.57M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Mitchell P. KopinInsider | 13.17% | 6.00M | 13Gfiled Jan 23, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 6.38% | 2.91M | 13Fas of Mar 31, 2026 |
Joseph Mona1Insider10 percent owner | 5.26% | 2.40M | 13Gfiled Oct 21, 2019 ↗ |
CIBC Bancorp USA Inc.Institution | 4.10% | 1.87M | 13Fas of Mar 31, 2026 |
Susquehanna International Group, LLPInstitution | 2.03% | 924,307 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Joseph Mona's transaction reports restate only vehicles that traded; the 2019 ownership statement (2.40M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Stereotaxis
Robotic endovascular navigation across coronary, neuro, and EP labs
- Philips (ADR)
LumiGuide provides real-time 3D endovascular device navigation
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Microbot Medical | $1.49 | +1.20% | $66.5M | — | — | 192.3 | — |
| Stereotaxis | $1.36 | −2.16% | $135.1M | — | — | 4.5 | −12.8% |
| Philips (ADR) | $26.22 | −0.62% | $25.77B | 19.6 | 13.5 | 1.3 | −2.9% |
| Median | 19.6 | 13.5 | 2.9 | −7.9% |